Conditions/Oncologic surgery
Hereditary Cancers
Lynch, BRCA, FAP, CDH1, and related syndromes — in surgical patient language
Most cancers are not inherited. Some findings change family screening and treatment choices.
Most cancers are sporadic. Lynch, BRCA1/2, FAP, CDH1, Li-Fraumeni, Peutz–Jeghers, and selected other germline conditions can raise risk for the patient and relatives. This hub is not a genetics clinic: it answers common surgical-patient questions and links to molecular testing. Tumor (somatic) results are not the same as germline results — confusing them causes unnecessary fear or missed cascade testing.
Educational figures
Tap a figure to enlarge. These English illustrations mirror the Turkish hub gallery for this condition.
Overview FAP BRCA Counseling
Lynch / FAP
Colorectal risk via MMR/MSI or polyposis pathways.
BRCA / CDH1
Breast–ovarian or hereditary diffuse gastric risk.
Rarer syndromes
Li-Fraumeni, Peutz–Jeghers — counseling first.
Molecular link
Tumor testing ≠ automatic hereditary diagnosis.
What to know
- When to think hereditaryTap for details
Young-onset cancer, multiple primaries, first-degree relatives with related cancers, a known family mutation, or dMMR/MSI-H on pathology are clues to discuss genetics — not reasons to panic alone.
- Tumor vs germlineTap for details · key note insideNoteDeclining germline counseling is not the same as skipping tumor MMR testing.
Somatic tumor tests guide treatment. Germline tests need separate consent and counseling; cascade testing for relatives follows pathogenic germline findings only.
- What this hub is notTap for details
It does not diagnose syndromes, order panels, or sell “miracle screening packages.” It helps you ask the right questions and find the molecular-testing pages.
Patient journey
In this hub — follow the pathway step by step. Full Turkish illustrated pages remain linked from each chapter.
- 1
Hereditary Cancer Overview
When hereditary risk is considered and how sequencing works
Read this chapter - 2
Lynch Syndrome
MMR/MSI, colorectal risk, and family screening
Read this chapter - 3
BRCA and Familial Breast Risk
Who is offered testing; surgery and surveillance frame
Read this chapter - 4
FAP
Polyposis, APC, and surgical timing
Read this chapter - 5
CDH1
Hereditary diffuse gastric cancer risk
Read this chapter - 6
Li-Fraumeni Syndrome
TP53 and multi-cancer spectrum
Read this chapter - 7
Peutz–Jeghers Syndrome
Hamartomatous polyps and surveillance
Read this chapter - 8
Genetic Counseling
Consent, results, and talking with relatives
Read this chapter - 9
Molecular Testing in Cancer
Organ-specific biomarkers that often open this conversation
Read this chapter
Appointment / info
Bring pathology, family history notes, and any prior genetic reports — we clarify which questions matter next.
This page is for education. It is not medical advice and does not replace genetic counseling or a visit with your physician.
Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · English patient-education hub.